MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: A randomized, controlled trialFredrick M. Wigley, Vivien Hsu, Naomi F. Rothfield et al.|Arthritis & Rheumatism|2009Cited by 110
Safety and tolerability of MQX-503, a novel investigational topical formulation of nitroglycerin for the treatment of Raynaud's phenomenonNaomi F. Rothfield, Fredrick M. Wigey, Lee Shapiro et al.|Lund University Publications (Lund University)|2008Cited by 1
MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon:A randomized, controlled trialNaomi F. Rothfield, Fredrick M. Wigey, Lee Shapiro et al.|Discovery Research Portal (University of Dundee)|2008Cited by 0